Your session is about to expire
← Back to Search
Behavioral Nudges for Flu Vaccination Compliance (BE IMMUNE Trial)
N/A
Waitlist Available
Led By Shivan Mehta, MD,MBA,MSHP
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
BE IMMUNE Trial Summary
This trial will test how well personalized messages to patients and doctors help increase flu vaccine rates among seniors. Patients get pre-visit reminders and doctors get feedback/default orders in their EHR. High-risk patients get extra text messages.
Who is the study for?
This trial is for adults over 50 who have a primary care appointment at Penn Medicine, UW Medicine, or Sutter Health during flu season and haven't had their flu shot yet. It's especially focused on those 70+, from low-income areas, didn't get vaccinated last year, or are Non-Hispanic Black.Check my eligibility
What is being tested?
The study tests if personalized 'nudges' to both doctors and patients can increase flu vaccinations. This includes pre-visit texts for patients, automatic vaccine orders in patient records for clinicians, and extra messages for high-risk patients.See study design
What are the potential side effects?
Since this trial involves communication strategies rather than medications, there are no direct medical side effects. However, participants may experience an increased number of notifications related to the flu vaccination.
BE IMMUNE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of patients who receive the flu vaccine at the visit
Secondary outcome measures
Proportion of patients who receive the flu vaccine within 3 months after the visit
BE IMMUNE Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Intervention ArmExperimental Treatment3 Interventions
Clinics randomized to the intervention arm will receive the toolkit of clinician and patient facing nudges. Patient nudges will be pre-visit text message reminders (standard messaging content). Clinician nudges will be monthly peer comparison feedback and default pended orders.
Group II: High Risk Intensification ArmExperimental Treatment4 Interventions
Patients in the intervention clinics identified as high risk for noncompletion of the flu vaccine will be randomized 1:1 to receive the high risk intensification arm or remain in the standard intervention arm. Patients in the high risk intensification arm will receive an additional bidirectional texting component.
Group III: ControlActive Control1 Intervention
Clinics randomized to the control arm will receive standard of care.
Find a Location
Who is running the clinical trial?
National Institute on Aging (NIA)NIH
1,669 Previous Clinical Trials
27,924,899 Total Patients Enrolled
13 Trials studying Health Behaviors
270,163 Patients Enrolled for Health Behaviors
University of PennsylvaniaLead Sponsor
2,000 Previous Clinical Trials
42,799,873 Total Patients Enrolled
7 Trials studying Health Behaviors
103,444 Patients Enrolled for Health Behaviors
University of WashingtonOTHER
1,738 Previous Clinical Trials
1,764,136 Total Patients Enrolled
4 Trials studying Health Behaviors
649 Patients Enrolled for Health Behaviors
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any vacancies available for participants in this trial?
"Per the clinicaltrials.gov database, this study is no longer enrolling patients as it was last updated on September 25th 2023. Despite this, there are 153 other trials currently recruiting participants."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger